Spotlight Hits This Little-Known Generic Biotech That Raised Price of Schizophrenia Drug by 1,650%

Starting in April, a little-known generic drug company in Philadelphia suddenly raised the price of fluphenazine, a medication used to treat symptoms of certain types of schizophrenia, by 1,650% over a three-month period. The evidence: Prescription tracking firm IMS Health discloses the number of times a medicine is prescribed and the medicine’s gross sales. IMS tracked 32,072 prescriptions of fluphenazine in in the first three months of 2016, generating $358,000 and yielding a net price of $11.17. Between April and June, there were 37,320 prescriptions at a net price of $195.53, generating $7.3 million in sales over the three-month period.